Evidence map›Paper›PMID 42376990›Full record

ArticleAntimicrobial agents and chemotherapy2026

Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway.

Zheng Sun, Yixuan Huang, Rui Guo, Tao Jiang, Qingru Chen, Xinyu Zhang, Jiling Liu, Qi Tang, Mingwei Chen, Shenghai Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zheng Sun *School of Life Sciences, Anhui Medical University, Hefei, Anhui, China.
Yixuan Huang *Department of Endocrinology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Rui GuoDepartment of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
Tao JiangDepartment of Neurosurgery, Anhui Public Health Clinical Center (North District, the First Affiliated Hospital of Anhui Medical University), Hefei, Anhui, China.
Qingru ChenSchool of Life Sciences, Anhui Medical University, Hefei, Anhui, China.
Xinyu ZhangDepartment of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
Jiling LiuDepartment of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
Qi TangDepartment of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.ORCID 0000-0002-4818-5492
Mingwei ChenDepartment of Endocrinology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.ORCID 0000-0002-8439-0469
Shenghai HuangDepartment of Microbiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.ORCID 0000-0002-5699-8928

Funding

Major Project of Natural Science Research of Anhui Education Department no. KJ2019ZD23National first-class undergraduate major construction point (Biotechnology)National Key Research and Development Program of China 2023YFC2604300 and 2024YFC2310400National Natural Science Foundation of China no. 81974306
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infections in infants and young children worldwide. Safe and effective treatments for RSV remain limited. In this investigation, we screened more than 100 anti-influenza compounds from a small-molecule library using an A549 cell model. Among these drugs, lapatinib emerged as a promising candidate and demonstrated potent anti-RSV activity along with low cytotoxicity. Lapatinib not only significantly suppressed RSV replication

Indexed as

Antiviral AgentsInterleukin-17LapatinibRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsA549 CellsAnimalsErb-b2 Receptor Tyrosine KinasesErbB ReceptorsFemaleHumansMiceMice, Inbred BALB CSignal TransductionVirus ReplicationAntiviral AgentsErb-b2 Receptor Tyrosine KinasesErbB ReceptorsInterleukin-17Lapatinibantiviral activityIL-17inflammatory factorslapatinibRSV

Identifiers

PMID42376990
PMCPMC13436392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.